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Abstract
Background: Two studies using
31P-magnetic resonance spectroscopy (MRS) reported enhanced phosphocreatine (PCr)
levels in normal appearing white matter (NAWM) of subjects with multiple sclerosis (MS), but this finding could not be
properly explained.
Methodology/Principal Findings: We performed
31P-MRS and
1H-MRS in the NAWM in 36 subjects, including 17 with
progressive MS, 9 with benign MS, and 10 healthy controls. Compared to controls, PCr/b-ATP and PCr/total
31P ratios were
significantly increased in subjects with progressive MS, but not with benign MS. There was no correlation between PCr
ratios and the N-acetylaspartate/creatine ratio, suggesting that elevated PCr levels in NAWM were not secondary to axonal
loss. In the central nervous system, PCr is degraded by creatine kinase B (CK-B), which in the white matter is confined to
astrocytes. In homogenates of NAWM from 10 subjects with progressive MS and 10 controls without central nervous system
disease, we measured CK-B levels with an ELISA, and measured its activity with an enzymatic assay kit. Compared to
controls, both CK-B levels and activity were decreased in subjects with MS (22.41 versus 46.28 mg/ml; p=0.0007, and 2.89
versus 7.76 U/l; p,0.0001).
Conclusions/Significance: Our results suggest that PCr metabolism in the NAWM in MS is impaired due to decreased CK-B
levels. Our findings raise the possibility that a defective PCr metabolism in astrocytes might contribute to the degeneration
of oligodendrocytes and axons in MS.
Citation: Steen C, Wilczak N, Hoogduin JM, Koch M, De Keyser J (2010) Reduced Creatine Kinase B Activity in Multiple Sclerosis Normal Appearing White
Matter. PLoS ONE 5(5): e10811. doi:10.1371/journal.pone.0010811
Editor: Christoph Kleinschnitz, Julius-Maximilians-Universita ¨tW u ¨rzburg, Germany
Received March 28, 2010; Accepted May 5, 2010; Published May 25, 2010
Copyright:  2010 Steen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Stichting MS-Anders, Amsterdam, The Netherlands. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Jacques.DeKeyser@uzbrussel.be
. These authors contributed equally to this work.
Introduction
Relapses and progression are the two basic clinical courses of
multiple sclerosis (MS), which is traditionally viewed as a T-cell
driven autoimmune disease against myelin. There is substantial
evidence that inflammation plays a role in relapses, but whether
this is a primary or secondary phenomenon remains a matter of
controversy. Pathological studies have shown that early lesions and
some evolving focal demyelinating lesions are characterized by
oligodendrocyte apoptosis with little or no lymphocytic infiltration
[1–3]. The progressive phase of MS reflects an insidious axonal
degeneration that is age related, and independent of relapses
[4–5]. The pathophysiological mechanism underlying this diffuse
axonal degeneration is unknown. There is little evidence that
inflammatory mechanisms play a primary role in this process as
immunomodulatory drugs are ineffective in progressive MS.
Demyelination and axonal degeneration in MS continue despite
pronounced immunosuppression [6].
Astrocytes in the white matter extend thin processes that contact
axons at the nodes of Ranvier, where they are presumed to
participate in the regulation of homeostatic and metabolic
functions necessary for a proper activity of axons [7]. These
astrocytic end-feet are too thin to contain mitochondria [8], and
energy metabolism is locally supplied by glycolysis, glycogenolysis
and phosphocreatine (PCr) breakdown [9]. PCr, a smaller
molecule than adenosine triphosphate (ATP), is generated by
mitochondria and diffuses in the astrocytic processes where it is
degraded by creatine kinase B (CK-B) to deliver ATP. Free
creatine (Cr), formed by the removal of phosphate from PCr, then
diffuses back to the mitochondria for rephosphorylation
(Figure 1). It has been shown by immunohistochemistry that
CK-B in both adult human and adult mice white matter is
confined to astrocytes [10][11][12]. The most ATP consuming
activity in astrocytic processes during axonal electrogenesis is the
Na
+/K
+-ATPase. It takes up K
+ released by axons in the
extracellular space after each depolarization, and it establishes
the Na
+ gradient necessary for glutamate uptake by the astrocytic
Na
+-dependent glutamate transporter (Figure 1) [13][14].
Two previous studies using
31phosphorus magnetic resonance
spectroscopy (
31P-MRS), reported that normal appearing white
matter (NAWM) PCr/b-ATP and PCr/total
31P ratios were
higher in MS subjects than in healthy controls [15][16]. As there
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10811was no clear explanation, these findings have received little further
attention. In the present study we sought to confirm the previous
findings, relate PCr levels to the degree of axonal loss, and assess
CK-B activity and levels in NAWM of subjects with MS.
Materials and Methods
Subjects
The Ethics Committee of the University Medical Center of
Groningen approved the MRS studies, and all subjects provided
written informed consent. Thirty-six subjects including 17 with
progressive MS (9 primary and 8 secondary), 9 with benign MS,
and 10 healthy controls (Table 1) were included. Benign MS
subjects had Extended Disability Status Scale scores of #3 at least
15 years after disease onset. All MS subjects were clinically stable
without evidence of an acute exacerbation within the 3 months
prior to scanning. Besides one patient with secondary progressive




MRI scans of the brain were obtained using a 3 Tesla Philips
MRI system with either the 8-channel SENSE head coil for
1H
MRS, or the phosphorus surface coil (diameter 14 cm) for
31P
MRS.
1H MRS was preceded by the acquisition of a transverse 3D
T1-weighted scan, which was reformatted to obtain coronal and
sagittal series. This allowed accurate positioning of the 2D
spectroscopic imaging slab, containing multiple voxels of
1.5 cm
3, in the centrum semiovale above the corpus callosum
(Figure 2). Water suppressed single slice PRESS was used with
the following scan parameters: echo time =144 ms, repetition
time =2 s, slice thickness 1.5 cm, in plane resolution 161c m
3,
spectral bandwidth 2000 Hz and 1024 sample points. Signal from
skull fat was suppressed by placing 10 saturation bands in a
Figure 1. Proposed model of PCr metabolism in astrocytes. PCr generated by mitochondria diffuses in the astrocytic processes where it is
degraded by CK-B to deliver ATP. Free Cr, formed by the removal of phosphate from PCr, diffuses back to the mitochondria. This local energy is
required for the Na
+/K
+-ATPase, which removes K
+ generated during axonal electrogenesis from the extracellular space, and establishes the Na
+
gradient required for Na
+-dependent glutamate uptake by astrocytes. Transcription of CK-B appears to be mediated by cAMP [23][24].
doi:10.1371/journal.pone.0010811.g001
Table 1. Clinical characteristics of healthy controls and MS subjects in the MRS studies.
Healthy controls n=10 Benign MS n=9 Progressive MS n=17
Male/female 5/5 5/4 9/8
Age (years), mean 6 SD 49.7 (6.3) 51.0 (5.2) 50.5 (7.3)
Disease duration (years), mean 6 SD - 19.1 (5.9) 21.0 (12.0)
Expanded Disability Status Scale (range) - 1.6 (0–2.5) 5.3 (4.0–6.5)
doi:10.1371/journal.pone.0010811.t001
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8 min. N-acetylaspartate (NAA) peak areas were analyzed
bilaterally in the 12 voxels corresponding to the centrum
semiovale, with exclusion of voxels including lesions, and
expressed as ratios to Cr, which is assumed to be relatively stable
[17] (Figure 2).
31P MRS was preceded by the acquisition of transverse, sagittal
and coronal MRI series in order to position the volume of interest
(66363o r6 62.563c m
3; 45–54 cc) in the right centrum
semiovale (Figure 3). The distance between the center of the
surface coil and the middle of the volume of interest was always
less than 7 cm, to allow for good quality spectra. Scan parameters
were: repetition time =4.5 s, spectral bandwidth 3000 Hz, 1024
sample points, and 256 measurements were averaged for the
decoupled spectra. The volume of interest contained on average 3
(0–9) visible focal lesions in the whole patient group. However, the
total lesion volume was very small compared to the total volume of
interest, reflecting less than 5% of the total volume. Cortical grey
matter contamination in the volume of interest was also below 5%.
Total scan time was around 20 min. The processed spectra
obtained by
31P MRS were curve fitted to provide metabolite peak
areas (Figure 3). The
31P spectra showed peaks of PCr, inorganic
phosphate (Pi), the three phosphates of ATP (a- ATP, b-ATP, c-
ATP), phosphorylethanolamine (PE) and phosphorylcholine (PC)
= phosphomonoesters (PME), glycerophosphorylethanolamine
(GPE) and glycerophosphorylcholine (GPC) = phosphodiesters
(PDE). In the statistical analysis the ratios PCr/b-ATP, PCr/total
31P and PCr/Pi were used as measures of the PCr energy status.
Total ATP/total
31P was also computed and the ratios of PME
and PDE to b-ATP were included as well. b-ATP is used as
reference for ATP because it does not contain contributions of
other compounds known to be present in brain tissue [17].
NAWM was defined as white matter outside the T2-hyperintense
foci on brain MRI.
Post-mortem brain tissue
Frozen brain samples were obtained from the Netherlands
Brain Bank (Amsterdam, the Netherlands) and the UK Multiple
sclerosis tissue bank (London, UK). We investigated NAWM from
brain slices from 10 patients who had died with secondary
Figure 2.
1H Magnetic resonance spectroscopy. (A) Slab with multiple voxels placed in the centrum semiovale for
1H MRS and (B)
1H-spectrum
showing the peaks for choline (Cho), creatine (Cr), and N-acetylaspartate (NAA).
doi:10.1371/journal.pone.0010811.g002
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postmortem time 963 h), and 10 controls without CNS disease
(age at death 71611 years; 5 women and 5 men; postmortem time
863 h). Age and postmortem intervals were not significantly
different between MS patients and controls p=0.105; p=0.596).
Creatine kinase B
Equal amounts (500 mg) of frozen macroscopically NAWM
samples were homogenized with a Teflon-glass homogenizer in
ice-cold 50 mM Tris buffer, pH 7.6. Homogenates were centri-
fuged at 600 x g for 10 min, the pellet was discharged and the
supernatant was centrifuged at 8000 x g for 20 min. The
supernatant of the second centrifugation was collected for
determination of cytosolic CK, which represents CK-B. This
separation procedure was used to remove the mitochondrial CK
fraction.
CK-B concentrations were assessed using a non-competitive
sandwich ELISA. A monoclonal mouse anti-human CK-B, a
polyclonal antibody rabbit anti-human CK-B and purified CK-B
protein were obtained from Abcam (Cambridge, UK). The anti-
human CK-B antibody reacts only with the CK-BB dimer, and
not with the B subunit of CK-MB. A 96-well plate was coated with
100 ml per well of monoclonal anti-human CK-B antibody (diluted
to 0.5 mg/ml with 0.05 M sodium bicarbonate, pH 9.6) and
incubated overnight at 4uC. Wells were washed once with 300 ml
Tris buffered saline (20 mM Tris and 150 mM NaCl) containing
0.1% Tris-Buffered Saline Tween-20 using a microplate washer.
The plate was then blocked for 1 h with blocking buffer (200 ml
per well) consisting of 1% bovine serum albumin made up in
Dulbecco’s phosphated buffer saline (pH 7.35). The blocked plate
was washed once with 300 ml Tris-Buffered Saline Tween-20. CK-
B protein standards were made in Dulbecco’s phosphated buffer
saline at final concentrations of 0.22 mg/ml, 2.2 mg/ml, 22 mg/ml
and 220 mg/ml. Standards and cytosolic white matter samples
were added (100 ml per well) and the plate was incubated at room
temperature for 2 h. Wells were washed 4 times with 300 ml Tris-
Buffered Saline Tween-20. Thereafter, each well was incubated
with 100 ml of rabbit anti-human CK-B diluted in Dulbecco’s
phosphated buffer saline (0.5 mg/ml) for 2 h at room temperature.
The plate was washed four times with 300 ml Tris-Buffered Saline
Tween-20, and after washing each well was incubated with 100 ml
polyclonal anti-rabbit-HRP (0.2 mg/ml). The plate was then
Figure 3.
31P Magnetic resonance spectroscopy. (A) Volume of interest in the centrum semiovale for
31P MRS. (B) Typical decoupled
31P-
spectrum with the peaks for PCr, phosphorylethanolamine (PE), phosphorylcholine (PC), inorganic phosphate (Pi), glycerophosphorylethanolamine
(GPE), glycerophosphorylcholine (GPC), and the three peaks for ATP.
doi:10.1371/journal.pone.0010811.g003
Creatine Kinase B in MS
PLoS ONE | www.plosone.org 4 May 2010 | Volume 5 | Issue 5 | e10811incubated in the dark at room temperature for 1 h. After washing,
100 ml per well of substrate (1-step Ultra TMB-ELISA, Pierce,
Rockford, IL) was added and the plate was incubated for 10 min
in the dark. Color change was monitored visually. The reaction
was stopped by the addition of 100 ml of 1 N HCl per well.
Absorbance at 450 nm was read on a spectrophotometer.
Cytosolic CK activity was assayed using an EnzyChrom
TM CK
Assay Kit (BioAssay Systems, Hayward, CA). The assay is based
on enzyme-coupled reactions in which PCr and asdenosine
diphosphate (ADP) is converted to Cr and ATP by CK. The
generated ATP is used to phosphorylate glucose by hexokinase to
generate glucose-6-phosphate, which is then oxidized by nicotin-
amide adenine dinucleotide phosphate (NADP) in the presence of
glucose-6-phosphate dehydrogenase. The rate of change of NADP
absorbance, measured at 340 nm, is proportionate to the CK
activity in the sample. Activity measurement was initiated by the
addition of PCr. Withholding PCr addition until all the
endogenous ATP was consumed in the CK reaction compensated
for the presence of endogenous ATP in the samples.
Statistics
The Kruskal-Wallis test was used to evaluate group differences
in MRS with GraphPad Prism version 4.00 for Windows (San
Diego, CA). When a statistically significant difference was found,
the Dunn test was applied to assess differences. Associations were
assessed by Spearman’s rank-correlation coefficient. We evaluated
the correlation between NAA/Cr and PCr/b-ATP or PCr/total
31P by partial correlation testing, controlling for age and sex, by
using the statistical package for Social Sciences (SPSS 12.0 for
Windows, Chicago, IL). Comparisons between MS subjects and
controls for CK assays were performed by means of the Mann–
Whitney U test. Results are expressed as means 6 standard
deviation. All reported p values are two sided.
Results
MRS
1H MRS in the NAWM of the centrum semiovale showed a
difference in NAA/Cr ratio between the three groups (p=0.02),
which was explained by a reduction in the progressive MS group
compared to healthy controls (Dunn’s post test p,0.05) (Table 2).
Some decrease was also observed in the benign MS group, but the
difference with the healthy controls was not significant.
31P MRS showed a significant difference among the 3 groups in
the PCr/b-ATP ratio (p=0.02) and PCr/total
31P ratio (p=0.03),
which was explained by an increase in the progressive group
compared to healthy controls (Dunn’s post test p,0.05) (Table 2).
Compared to the healthy controls, PCr/b-ATP and PCr/total
31P
ratios were slightly increased in benign MS subjects, but this was
not significant. There were no differences between MS subjects
and controls with regard to the other metabolite ratios.
Considering the whole MS group, there was no correlation
between the NAA/Cr ratio and both PCr/b-ATP and PCr/total
31P ratios (Figure 4).
Creatine kinase B
CK-B levels in the NAWM were lower in the MS subjects
(22.41611.51 mg/ml) than in the controls (46.28614.60 mg/ml;
p=0.0007). White matter cytosolic CK activity, which corre-
sponds to CK-B activity, was lower in the MS subjects
(2.8961.53 U/l) than in the controls (7.7661.30 U/l;
p,0.0001). Box plots of the CK-B levels and cytosolic CK activity
are shown in Figure 5. There was a good correlation between
CK-B levels and activity (r=0.650; p=0.0019).
Discussion
Our finding of increased PCr/b-ATP and PCr/total
31P ratios
in the NAWM of subjects with progressive MS is in accordance
with two previous studies [15][16]. Since
31P MRS has less spatial
resolution than
1H MRS, a larger volume of interest is needed,
and such a larger volume can contain some focal MS lesions and
adjacent cortical grey matter. However, considering the whole MS
group, both total lesion volume and cortical grey matter
contamination was each less than 5%. Similar to the two previous
studies we measured PCr ratios, and not estimated absolute values
for PCr, which require the use of calibrated phantoms for each
patient. b-ATP/total
31P ratios were not different between MS
subjects and controls, indicating that the elevated PCr/b-ATP and
PCr/total
31P ratios in the NAWM in MS reflect elevated PCr
levels.
Compared to controls, patients with benign MS showed a trend
for elevated PCr ratios in the NAWM but the difference was not
significant. NAA is an amino acid produced by mitochondria in
neurons, and the NAA/Cr ratio is regarded as a measure for
axonal function and integrity. The lack of correlation between the
NAA/Cr ratio and PCr/b-ATP and PCr/total
31P ratios suggests
that the PCr increase in progressive MS is not secondary to axonal
dysfunction or loss. Another argument against a secondary
phenomenon is that PCr ratios were not elevated in focal MS
lesions [16].
Our results suggest that a reduced PCr metabolism in the
NAWM in progressive MS is caused by decreased activity of CK-
B, which is confined to astrocytes [10][11][12]. Unfortunately, it is
impossible to analyse PCr in postmortem brain samples, because
PCr degradation starts already within a few minutes after death. In
rabbit brain studied 1 h after death PCr was no longer measurable
[18].
It has been suggested that oxidative stress may reduce CK-B
activity [19]. A number of studies found evidence of increased
production of reactive oxygen species in inflammatory lesions,
cerebrospinal fluid and plasma of subjects with MS
[20][21][22]. However, loss of CK-B activity by oxidative stress
appears to be caused by posttranslational oxidative modification
of the enzyme [19]. In our MS samples, the levels of CK-B were









NAA/Cr 2.19 (0.16) 2.06 (0.22) 2.00 (0.21)#
PCr/b-ATP 1.95 (0.28) 2.19 (0.35) 2.42 (0.64)#
PCr/total
31P 0.21 (0.02) 0.23 (0.04) 0.25 (0.04){
PCr/Pi 3.43 (0.54) 3.64 (0.88) 3.89 (0.81)
PME/b-ATP 0.66 (0.15) 0.70 (0.20) 0.72 (0.16)
PDE/b-ATP 1.61 (0.23) 1.75 (0.30) 1.55 (0.30)
Total ATP/total
31P 0.46 (0.03) 0.455 (0.02) 0.45 (0.03)
b-ATP/total
31P 0.11 (0.01) 0.10 (0.01) 0.11 (0.02)
Values are mean 6SD.
PCr, phosphocreatine; Cr, creatine; NAA, N-acetylaspartate; Pi, inorganic
phosphate; PME, phosphomonoesters; PDE, phosphodiesters; ATP, adenosine
triphosphate; P, phosphorus.
#p=0.02; { p=0.03 (Kruskal-Wallis, followed by Dunn test).
doi:10.1371/journal.pone.0010811.t002
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s c r i p t i o no fC K - Bi nh u m a na s t r o g l i a lc e l l sin vitro is induced by
cAMP [23][24]. White matter astrocytes contain b2 adrenergic
receptors, which upon activation by norepinephrine increase the
l e v e l so fc A M P[ 2 5 ] .W eh a v ep r e v i o u s l yr e p o r t e dt h a t ,i n
contrast to other forms of CNS injury, astrocytes in MS cerebral
white matter are deficient in b2 adrenergic receptors [25]. A
deficiency in astrocytic b2 adrenergic receptors might provide
an explanation for the decrease in white matter CK-B levels.
However, this relationship is at this moment speculative, and
warrants further research.
It is tempting to speculate that a reduced energy metabolism in
astrocytic axonal end-feet during increased demands might play a
role in the degeneration of oligodendrocytes and axons in MS.
The propagation of action potentials along myelinated axons not
only leads to expulsion of K
+ but also to rapid vesicular release of
glutamate at the nodes [26]. At the level of the astrocyte endings,
glutamate uptake is accomplished by Na
+-dependent transporters
[13][14], which move glutamate into astrocytes against a steep
concentration gradient by coupling glutamate translocation to the
transmembrane Na
+,K
+ gradients. These gradients are main-
tained by membrane Na
+/K
+-ATPase, such that glutamate uptake
is ultimately ATP dependent. Reduced activity of the astrocytic
Na
+/K
+-ATPase will lead to higher extracellular K
+ concentra-
tions and may induce reversal of glutamate uptake by glutamate
transporters [27]. Support for a role of PCr in astrocyte glutamate
uptake has been obtained in experiments showing that a glutamate
challenge to cultured astrocytes was associated with enhanced PCr
consumption [28][29].
Glutamate toxicity might be responsible for apoptotic cell
death of oligodendrocytes in MS [30][31]. However, it is likely
that additional factors are required to explain why this has a
tendency to occur in a focal and not in a more diffuse manner.
Glutamate toxicity might provide an explanation for the diffuse
Figure 4. Correlation between NAA/Cr and PCr/total
31P and PCr/b-ATP in the MS subjects.
doi:10.1371/journal.pone.0010811.g004
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express functional a-amino-3-hydroxyl-5-methyl-4-isoxazole-
propionic acid (AMPA) and kainate receptors, which upon
overstimulation lead to an increase of intra-axonal Ca
2+ levels
[33][34]. Abnormally increased Ca
2+ in axons will activate
catabolic enzymes, impair mitochondrial function and axonal
transport, and this may lead to axonal degeneration [35]. It has
been suggested that glutamate toxicity might be further
exaggerated by inflammation, because glutamate is also
released in large quantities by activated immune cells [32]
[36]. Elevated glutamate levels have been demonstrated
throughout the brain NAWM [37], and in the cerebrospinal
fluid of subjects with MS [38]. The expression of glutamate
transporters in MS white matter is increased, which constitutes
a known regulatory response of glial cells to toxic levels of
glutamate [39].
In summary, we show reduced CK-B activity in postmortem
obtained NAWM of subjects with progressive MS. Our data
raise the possibility that this may be responsible for a defective
PCr metabolism in astrocytes. We speculate that this abnor-
mality might provide an explanation for glutamate toxicity
thought to be responsible for the degeneration of oligodendro-
c y t e sa n da x o n si nM S .F u r t h e rin vivo studies are required to
investigate in more detail the role of PCr metabolism in
astrocyte glutamate uptake, as this may provide new insights in
the pathogenesis of MS.
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